PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on antiviral therapeutics that entered the public markets through a de-SPAC merger with LifeSci Acquisition 2 Corp, a blank-check vehicle sponsored by LifeSci Capital LLC that completed its IPO in 2021. After discontinuing its lead COVID-19 oral antiviral candidate, PBI-0451, in early 2023 following a review of clinical data, the company shifted focus toward evaluating strategic alternatives. The July 2023 Form 8-K reflects Pardes's continuing SEC disclosure obligations during that corporate review period. For comprehensive filing histories, de-SPAC deal timelines, and post-merger performance data on PRDS and thousands of other transactions, sign up for full access at SpacDesk.